Eli Lilly trial reveals Alzheimer's drug that significantly slows cognitive decline

Study examined the safety and efficacy of the study drug donanemab in participants with early Alzheimer's disease (AD).

Related Keywords

Eli Lilly ,Anne White ,National Coverage Determination ,Centers For Medicare Medicaid Services ,Drug Administration ,Donanemab Significantly Slowed Cognitive ,Functional Decline ,Early Alzheimer ,Image Credit ,Disease Rating Scale ,Clinical Dementia Rating Sum ,Lilly Neuroscience ,Medicaid Services ,National Coverage ,Alzheimer 39s Disease ,Amyloid Plaque ,Ntibody ,Rain ,Clinical Trial ,Dementia ,Efficacy ,Pathology ,Placebo ,Protein ,